OnKure Therapeutics, Inc.

NASDAQ:OKUR

Biotechnology

Healthcare
$2.82 +0.23%

+$0.01 today

Market cap
$114.22M
Beta
0.28
P/E (TTM)
-1.0
EPS (TTM)
-$4.30
52W Low $1.91High $5.38

Volume 0.17M

Average 0.37M

OKUR EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

OnKure Therapeutics, Inc.NASDAQ: OKUR

EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026

EPS (Basic) remains negative

Q1 FY2026 EPS (Basic) was -$1.11, compared with -$1.19 a year earlier. Trailing-twelve-month EPS (Basic) was -$4.33.

Context

  • EPS (Basic) grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 2 analysts of -$2.79 (+36.5%) for the fiscal year ending Dec 2026, a step up from the -11.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.11-12.1% QoQ
Last fiscal yearDec 2025
-$4.4-11.4% YoY
LTMMar 2026
-$4.33+16.2% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.7%+41.2%+34.5 pp
1 year-11.4%+36.5%+47.9 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

USD · from the income statement

Latest · FY2025
(4.40) USD
Year-over-year change
-11.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How OKUR compares with its peers on the latest reported figures

  • OKUR's LTM Mar 2026 EPS (Basic) of -$4.33 is the 3rd highest of the 4 companies compared; the peer median is -$0.67.
  • Its year-over-year change of +16.2% is the lowest of 4, against a peer median of +57.3%.
OKUR Competitors Peer median
EPS (Basic) for OKUR and competitors
Company Period LTM YoY 3-year CAGR
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$0.36 +127.5%—
PDSBPDS Biotechnology CorporationLTM Mar 2026-$0.67 +29.5%—
OKUROnKure Therapeutics, Inc.LTM Mar 2026-$4.33 +16.2%—
XLOXilio Therapeutics, Inc.LTM Mar 2026-$5.5 +57.3%—
Peer median (excluding OKUR) -$0.67+57.3%—

Competitors are the stored peer set for OKUR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue50K000830K
Gross Profit(50K)000(830K)
Gross Margin—————
Research & Development28.12M25.86M32.12M43.8M48.26M
Selling, General & Admin11.65M3.9M4.82M10.59M14.69M
Operating Expenses39.77M29.77M36.93M54.39M62.12M
Depreciation & Amortization50K387K560K662K830K
EBITDA(39.72M)(29.13M)(34.75M)(51.71M)(58.69M)
EBITDA Margin—————
Operating Income(39.82M)(29.77M)(36.93M)(54.39M)(62.95M)
Operating Margin—————
Interest Income0254K1.62M2.01M3.44M
Interest Expense000300K0
Other Income / Expenses48K254K1.62M1.71M3.43M
Income Before Tax(39.77M)(29.51M)(35.31M)(52.67M)(59.52M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(39.77M)(29.51M)(35.31M)(52.67M)(59.52M)
Net Margin—————
EPS (Basic)(21.92)(2.21)(2.65)(3.95)(4.40)
EPS (Diluted)(21.92)(2.21)(2.65)(3.95)(4.40)
Weighted Avg Shares1.81M13.34M13.34M13.34M13.52M
Weighted Avg Shares (Diluted)1.81M13.34M13.34M13.34M13.52M

OnKure Therapeutics, Inc.

NASDAQ:OKUR

Intrinsic Alpha fair value

Locked

Current Price

$2.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.